Experts agree that the earlier Alzheimer's disease is detected, the sooner action can be taken. And so, the key to preventing deterioration is identifying the most effective early biomarkers, those that can spot the disorder and help halt its progression. Recent advances in the field have pushed a new era of early detection through blood-based biomarkers and personalized medicine strategies based on each patient’s genetic, immunological and clinical profile.
Pulmonary arterial hypertension (PAH) is a life-threatening disease; vasodilators may aid in managing this condition, but their impact on prognosis is still limited, potentially due to a lack of biomarkers to guide therapy. Japanese researchers have presented results of their efforts to discover potential molecular markers that may predict response to pulmonary vasodilators.
Researchers at Seoul National University and the National Cancer Center examined public datasets from patients as well as the whole-exome sequence from one of their own patients, who developed radiation-induced sarcoma after treatment.
Minovia Therapeutics Ltd. has announced a $350,000 grant from Countdown for a Cure for a research proposal related to the development of novel mitochondrial blood-based biomarkers.
Chinese researchers have developed a new a circulating exosomal proteomic biomarker signature that may aid in the diagnosis of interstitial lung disease (ILD) in combination with computed tomography. Exosomes may contribute to lung disorders by carrying cargoes that promote inflammatory responses in immune and lung epithelial cells. The assay was performed in a case-control biomarker study; exosomes from 168 serum samples were extracted and submitted to proteomic analysis.
Heat shock protein family H member 1 (HSPH1) plays a key role in cellular stress and protein homeostasis, and it has been implicated in proliferation, invasion and metastasis of tumor cells. A recent study aimed to investigate the link between HSPH1 and the prognosis of HCC.
Calcific aortic valve disease (CAVD) is the most prevalent acquired valve heart disorder in aging populations. Its most severe form in aortic valve stenosis (AVS), with an average survival of 2-3 years once symptoms appear. The early diagnosis of AVS based on circulating biomarkers is crucial to label high-risk patients before they progress to the severe form.
Bladder cancer is among the 10 most frequent cancers around the world. While potentially effective treatments exist, they do not benefit all patients, so investigators continue to search for new targets. Researchers at Nanjing Drum Tower Hospital have identified sideroflexin 1 (SFXN1) as a potential therapeutic target.
Colorectal cancer is among the most common malignant tumor types and the second leading cause of tumor-related deaths worldwide. Tumor necrosis factor α-induced protein 8-like protein 2 (TIPE2) is a protein member of the TIPE family and highly expressed in immune cells. The prognostic impact and the relationship with tumor immunity of TIPE2 plus other immune markers such as CD8, CD20 and CD66b were evaluated in colorectal cancer by researchers from First Affiliated Hospital of Anhui Medical University and collaborators.
Triple-negative breast cancer (TNBC) accounts for a substantial proportion of all breast cancers and is the most aggressive form of the disease. Identifying potential therapeutic targets is critical because the cancer does not express the three surface receptors recognized by current targeted therapies.
RSS
